Evotec's Balancing Act: A Fortified Balance Sheet Meets a Boardroom Reset

Evotec holds €465.6M liquidity and cuts costs, but shares near 52-week low as partnerships lag. New leadership faces turnaround test.

The Göttingen-based drug discovery specialist finds itself in an unusual position this autumn: its financial foundation is arguably the strongest it has been in months, yet the share price tells a far more sobering story. Evotec closed the first half of 2026 with liquid assets of €465.6 million, bolstered by a €116.1 million convertible bond and roughly $100 million in proceeds from the sale of its Tubulis stake. Those moves, executed over the course of 2026, hand management the runway needed to execute its Horizon savings program without resorting to further capital measures.

That program, which targets annual cost reductions of €75 million by the end of 2027, comes with a heavy upfront price tag. Restructuring charges of €98.9 million hit the books in the first half, with a €42.3 million writedown on a Hamburg laboratory building accounting for a substantial slice of that total. The impairment underscores just how deeply the capacity adjustments are cutting into the company's substance — even as the cash buffer provides a cushion against further balance-sheet strain.

A Changing of the Guard

The financial repositioning has unfolded alongside a significant shake-up at the top. At the June annual general meeting, shareholders elected Dieter Weinand, a former Bayer executive board member, as the new chairman of the supervisory board. Dr. Wolfgang Hofmann also joined the oversight body, while Dr. Duncan McHale and Wesley Wheeler saw their mandates extended. Roughly 43.10 percent of the share capital was represented at the vote.

The supervisory board transition followed a finance chief handover just weeks earlier. Claire Hinshelwood took over as CFO from Paul Hitchin, who departed at the end of April for personal reasons. Within a matter of months, Evotec filled two pivotal leadership roles — a rapid reshuffle that arrives precisely when the operational picture is at its most strained.

Weinand's pharmaceutical pedigree is likely to be tested most acutely in the partnership arena, an area where Evotec has recently shown vulnerability. The company was forced to slash its 2026 guidance over the summer, blaming delayed milestone payments and partnership contracts that closed later than anticipated. The new leadership team inherits a growth narrative that needs recalibration, not merely refinement.

Core Strength Beneath the Surface

For all the top-line pressure, one segment is quietly outperforming. In Discovery & Preclinical Development (D&PD), net sales excluding strategic partnerships grew by more than 28 percent year-on-year in the first half. That suggests the underlying demand for Evotec's research services remains intact, even as the larger partnership agreements that once drove growth have either lapsed or yet to materialize.

Partnership progress, meanwhile, is not entirely absent. In May, Evotec and Almirall jointly nominated their first preclinical development candidate from their collaboration in medical dermatology. The company says the journey from target identification to candidate took just two years — a pace it cites as evidence of its platform's capabilities. For investors, such early milestones matter because they demonstrate that the collaboration pipeline continues to move forward despite the financial turbulence.

The Market's Verdict

None of this has translated into share-price momentum. The stock closed Friday at €3.37, a mere 5.5 percent above its 52-week low of €3.19, set just last month. The shares have shed 38 percent since the start of the year and stand roughly 57 percent below their 52-week high of €7.75, reached in November. Over a twelve-month horizon, the decline deepens to 45 percent.

Technical indicators offer little comfort. The relative strength index sits at 38.9, leaving the stock in damaged chart territory without having reached classic oversold conditions. A 33 percent gap below the 200-day moving average underscores how far the shares have drifted from their medium-term trend.

The financing measures have undeniably strengthened the balance sheet, but they have yet to convince the market that a durable turnaround is underway. What investors will be watching in the coming quarters is whether the core business momentum and partnership milestones can be sustained — and whether the liquidity reserve proves sufficient to carry the transformation program to completion without additional capital raises. The third-quarter report will offer the next data point.